List view / Grid view
This investment supports AstraZeneca’s strategy to drive the biopharma company's…
This investment supports AstraZeneca’s strategy to drive the biopharma company's development in the US.
The new manufacturing facility for antibody drug conjugates (ADCs) will…
The new manufacturing facility for antibody drug conjugates (ADCs) will be designed to have zero carbon emissions when operational, AstraZeneca stated.
The new industry collaboration aims to help decarbonise the global…
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
Johnson & Johnson have been shifted from the top position…
Johnson & Johnson have been shifted from the top position in the market capitalisation ranking for the first time, due to Eli Lilly having the largest growth during Q2 2023, research shows.
Former Senior Vice President, Head of Research and Product Development…
Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
AstraZeneca has announced plans to invest in a new facility,…
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
H1 financial results show AstraZeneca’s revenues grew by 23 percent…
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
After manufacturing delays, AstraZeneca will now provide the EU with…
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19,…
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have…
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
After the clinical trial for AZD1222 was halted last week,…
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
An agreement between AstraZeneca and the European Commission means the…
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
AstraZeneca plans to produce up to 400 million doses of…
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
Pharma executives are committed to bringing drugs to market to…
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
